Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Inc.

www.exelixis.com

Latest From Exelixis Inc.

Ipsen Sees First Mover Advantage In EU For Cabometyx In Liver Cancer

Ipsen CSO says CHMP recommendation for TKI Cabometyx should give it first mover advantage globally in liver cancer.

Approvals Business Strategies

Garland Takes Helm Of Portola At A Crucial Time

Portola touts exec's commercial management experience with Genentech success stories Avastin and Tarceva.

Commercial Sales & Earnings

Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market

Study of PD-L1/TKI combo succeeded in an all comers population across risk groups, which could be differentiating, for a while.

Exelixis: NCCN Change Supports Broader Use Of Cabometyx In Kidney Cancer

Latest set of oncology clinical practice guidelines issued in September highlight Cabometyx as preferred treatment option.

Reimbursement Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Exelixis Inc.
  • Senior Management
  • Michael M Morrissey, PhD, Pres. & CEO
    Christopher J Senner, EVP, CFO
    Peter Lamb, PhD, EVP, Scientific Strategy & CSO
    Gisela M Schwab, MD, Pres., Prod. Dev. & CMO
  • Contact Info
  • Exelixis Inc.
    Phone: (650) 837-7000
    210 East Grand Ave.
    P.O. Box 511 S. San Francisco, CA 94083-0511
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register